Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia

Blood Cancer J. 2015 Mar 13;5(3):e292. doi: 10.1038/bcj.2015.13.

Authors

Y Collette¹, T Prébet², A Goubard¹, J Adélaïde¹, R Castellano¹, N Carbuccia¹, S Garnier¹, A Guille¹, C Arnoulet², A Charbonier², M J Mozziconacci², D Birnbaum¹, M Chaffanet¹, N Vey²

Affiliations

¹ Centre de Recherche en Cancérologie de Marseille (CRCM) Inserm UMR 1068, Institut Paoli-Calmettes, Aix-Marseille Université UM 105, CNRS UMR 7258, Marseille, France.
² 1] Centre de Recherche en Cancérologie de Marseille (CRCM) Inserm UMR 1068, Institut Paoli-Calmettes, Aix-Marseille Université UM 105, CNRS UMR 7258, Marseille, France [2] Département d'hématologie, Institut Paoli-Calmettes, Aix-Marseille Université UM 105, CNRS UMR 7258, Marseille, France.

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Biomarkers, Pharmacological*
Chromosomes, Human, Pair 1 / genetics
Chromosomes, Human, Pair 9 / genetics
Female
Humans
Imidazoles / administration & dosage*
Intracellular Signaling Peptides and Proteins / genetics
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics*
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology
Pyridazines / administration & dosage*
Translocation, Genetic / genetics

Substances

Biomarkers, Pharmacological
Imidazoles
Intracellular Signaling Peptides and Proteins
Pyridazines
RCSD1 protein, human
ponatinib